The estimated Net Worth of Charles Mc Wherter is at least $2.1 Milhão dollars as of 19 January 2024. Charles Wherter owns over 18,403 units of Cymabay Therapeutics Inc stock worth over $588,700 and over the last 10 years he sold CBAY stock worth over $0. In addition, he makes $1,508,930 as Senior Vice President e Chief Scientific Officer at Cymabay Therapeutics Inc.
Sign up
Charles McWherter CBAY stock SEC Form 4 insiders trading
Charles has made over 14 trades of the Cymabay Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 18,403 units of CBAY stock worth $130,477 on 19 January 2024.
The largest trade he's ever made was exercising 21,749 units of Cymabay Therapeutics Inc stock on 18 July 2023 worth over $108,745. On average, Charles trades about 6,537 units every 109 days since 2015. As of 19 January 2024 he still owns at least 18,125 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Charles Wherter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles McWherter biography
Dr. Charles A. McWherter Ph.D. serves as Senior Vice President, Chief Scientific Officer of the Company. From 2007 to 2013, he served as out Senior Vice President, Research and Preclinical Development. From 2003 to 2007, he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc., a biopharmaceutical company. From 2001 to 2003, Dr. McWherter served as Vice President of Drug Discovery at Sugen, Inc., a biopharmaceutical company acquired by Pfizer Inc. in 2003. Dr. McWherter obtained his Ph.D. from Cornell University.
What is the salary of Charles McWherter?
As the Senior Vice President e Chief Scientific Officer of Cymabay Therapeutics Inc, the total compensation of Charles McWherter at Cymabay Therapeutics Inc is $1,508,930. There are 1 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.
How old is Charles McWherter?
Charles McWherter is 65, he's been the Senior Vice President e Chief Scientific Officer of Cymabay Therapeutics Inc since 2013. There are 2 older and 14 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.
What's Charles McWherter's mailing address?
Charles's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.
Insiders trading at Cymabay Therapeutics Inc
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster, eCarl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
What does Cymabay Therapeutics Inc do?
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
What does Cymabay Therapeutics Inc's logo look like?
Complete history of Charles Wherter stock trades at Cymabay Therapeutics Inc e 89bio Inc
Cymabay Therapeutics Inc executives and stock owners
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Sujal Shah,
President, Chief Executive Officer, Director -
Charles McWherter,
Senior Vice President, Chief Scientific Officer -
Klara Dickinson,
Chief Regulatory and Compliance Officer -
Daniel Menold,
Vice President - Finance -
Sujal A. Shah,
Pres, CEO & Director -
Dr. Charles A. McWherter Ph.D.,
Chief Scientific Officer -
Paul T. Quinlan,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Robert Wills,
Independent Chairman of the Board -
Kurt von Emster,
Independent Director -
Paul Truex,
Independent Director -
Caroline Loewy,
Independent Director -
Dr. Dennis D. Kim M.B.A., M.D., MBA,
Chief Medical Officer -
Becki Filice,
Sr. VP of Portfolio & Product Leadership -
Klara A. Dickinson-Eason,
Chief Regulatory & Quality Assurance Officer -
Dr. Robert L. Martin,
Sr. VP of Manufacturing & Nonclinical Devel. -
Patrick J. O'Mara,
Sr. VP of Bus. Devel. -
Ken Boehm,
Sr. VP of HR -
Daniel Menold,
VP of Fin. -
Evan A. Stein,
Director -
Robert F. Booth,
Director -
Carl Goldfischer,
Director -
Pol F Boudes,
Chief Medical Officer -
Robert J. Weiland,
Director -
Kirk Rosemark,
V.P. Regulatory & Quality -
Wart Harold Van,
President and CEO -
Emster Kurt Von,
Director -
Thomas G Wiggans,
-
Paul T Quinlan,
General Counsel -
Eric Lefebvre,
-
Harish Shantharam,
Chief Financial Officer -
Lewis J Stuart,
Chief Commercial Officer -
Patrick J. O Mara,
VP, Business Development -
Robert L. Martin,
Sr. Vice President -
Capital Advisors Llc Aghaza...,
-
Edward Penhoet,
Director -
Louis G Lange,
Director -
Hari Kumar,
Director -
Janet Dorling,
-
Dennis D Kim,
Chief Medical Officer